Similar articles for PMID: 27516088

Year	Number of Results
1946	1
1993	1
1997	1
2002	2
2003	1
2004	1
2005	2
2006	2
2007	3
2008	3
2009	2
2010	4
2011	4
2012	8
2013	14
2014	18
2015	23
2016	33
2017	31
2018	34
2019	23
2020	13
2021	23
2022	17
2023	4
2024	0

1

Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease: Analyses Conducted for Canada, France, Italy, and Portugal.

Reza Maleki-Yazdi M, Molimard M, Keininger DL, Gruenberger JB, Carrasco J, Pitotti C, Sauvage E, Chehab S, Price D. Reza Maleki-Yazdi M, et al. Appl Health Econ Health Policy. 2016 Oct;14(5):579-94. doi: 10.1007/s40258-016-0256-z. Appl Health Econ Health Policy. 2016. PMID: 27516088

2

Cost-effectiveness of the LABA/LAMA dual bronchodilator indacaterol/glycopyrronium in a Swedish healthcare setting.

Price D, Keininger D, Costa-Scharplatz M, Mezzi K, Dimova M, Asukai Y, Ställberg B. Price D, et al. Respir Med. 2014 Dec;108(12):1786-93. doi: 10.1016/j.rmed.2014.09.015. Epub 2014 Oct 2. Respir Med. 2014. PMID: 25307414 Free article. Clinical Trial.

3

Cost-effectiveness of indacaterol/glycopyrronium in comparison with salmeterol/fluticasone combination for patients with moderate-to-severe chronic obstructive pulmonary disease: a LANTERN population analysis from Singapore.

Tee A, Chow WL, Burke C, Guruprasad B. Tee A, et al. Singapore Med J. 2018 Jul;59(7):383-389. doi: 10.11622/smedj.2018022. Epub 2018 Mar 16. Singapore Med J. 2018. PMID: 29546433 Free PMC article.

4

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.

Chan MC, Tan EC, Yang MC. Chan MC, et al. Int J Chron Obstruct Pulmon Dis. 2018 Apr 4;13:1079-1088. doi: 10.2147/COPD.S159103. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 29670344 Free PMC article.

5

Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Patalano F, Banerji D. Zhong N, et al. COPD. 2016 Dec;13(6):686-692. doi: 10.1080/15412555.2016.1182970. Epub 2016 Aug 11. COPD. 2016. PMID: 27715335 Clinical Trial.

6

Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone in Patients with COPD-A Cost-Effectiveness Analysis in the Czech Republic.

Skoupa J, Kasak V, Klimes J, Valena T. Skoupa J, et al. Value Health Reg Issues. 2018 Sep;16:112-118. doi: 10.1016/j.vhri.2018.09.002. Epub 2018 Oct 27. Value Health Reg Issues. 2018. PMID: 30539739

7

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.

Bjermer L, van Boven JFM, Costa-Scharplatz M, Keininger DL, Gutzwiller FS, Lisspers K, Mahon R, Olsson P, Roche N. Bjermer L, et al. Respir Res. 2017 Dec 11;18(1):206. doi: 10.1186/s12931-017-0688-5. Respir Res. 2017. PMID: 29228950 Free PMC article. Clinical Trial.

8

LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D; LANTERN Investigators. Zhong N, et al. Int J Chron Obstruct Pulmon Dis. 2015 Jun 5;10:1015-26. doi: 10.2147/COPD.S84436. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26082625 Free PMC article. Clinical Trial.

9

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.

Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A. Rajagopalan K, et al. Int J Chron Obstruct Pulmon Dis. 2018 Nov 28;13:3867-3877. doi: 10.2147/COPD.S177097. eCollection 2018. Int J Chron Obstruct Pulmon Dis. 2018. PMID: 30568438 Free PMC article.

10

Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.

Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV; FLASH Investigators. Frith PA, et al. Respirology. 2018 Dec;23(12):1152-1159. doi: 10.1111/resp.13374. Epub 2018 Aug 3. Respirology. 2018. PMID: 30074294 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

254 results

Results by year